We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Jul 2020 - 30 Jul 2020

Sequencing Methods for Hepatitis C Virus Genotyping Compared

By LabMedica International staff writers
Posted on 04 Sep 2019
Print article
Image: The VERSANT HCV Genotype 2.0 Line Probe Assay (Photo courtesy of Siemens Healthcare Diagnostics).
Image: The VERSANT HCV Genotype 2.0 Line Probe Assay (Photo courtesy of Siemens Healthcare Diagnostics).
Due to its high rate of mutation, hepatitis C virus (HCV) forms viral quasispecies, classified based on the highly variable regions in the envelope protein and nonstructural 5B protein (NS5B). As a result of this large genetic variability, seven genotypes and more than 67 subtypes have been identified.

HCV genotyping is part of the evaluation of newly diagnosed patients and has always been important in guiding treatment. Considering that genotype is a key element in the management of patients infected with HCV, the determination of the genotype is recommended. The technique most frequently used to genotype HCV is quantitative real-time polymerase chain reaction (qRT-PCR). This technique is unable to provide an accurate genotype/subtype for many samples.

Microbiologists and their colleagues working at the Université Catholique de Louvain (Brussels, Belgium) develop an in-house method with the goal of accurately identifying the genotype of all samples. The team analyzed 100 samples from HCV infected patients by the VERSANT HCV Genotype 2.0 LiPA Assay covering frequent HCV types and subtypes. NS5B, 5’UTR and Core homemade sequencing were then performed on these samples. The sequences obtained were compared with the HCV genomic BLAST bank.

The investigators reported that all the samples were characterized by the VERSANT LiPA assay (eight G1a, 17 G1b, six G2, 11 G3, 13 G4, and 10 G6). It was not possible to discriminate between G6 and G1 by the VERSANT LiPA assay for eight samples and 27 had an undetermined genotype. Forty-one samples were sequenced for the three regions: NS5B, 5’UTR and Core. Twenty-three samples were sequenced for two regions: 5′ UTR and Core and 36 samples were sequenced only for NS5B. Of the 100 samples included, 64 samples were analyzed for 5’UTR and Core sequencing and 79 samples were analyzed for NS5B sequencing. The global agreement between VERSANT LiPA assay and sequencing was greater than 95%.

The authors concluded that the high genetic variability of HCV makes it a challenge to correctly determine genotype and subtypes using commercial assays. For undetermined samples, supplementary testing is required. They described new and original methods of sequencing 5’UTR and Core regions to confirm HCV genotypes not discriminated by a commercial assay, in particular by using amplicons already obtained by the VERSANT HCV Genotype 2.0 Line Probe Assay. The study was published on August 22, 2019, in the journal BMC Infectious Diseases.

Related Links:
Université Catholique de Louvain

Print article


Molecular Diagnostics

view channel
Image: Summary of changes FKBPL and CD44 changes throughout gestation in pregnancies complicated by pre-eclampsia (Photo courtesy of Oxford Press)

Elevated Levels of Two Protein Biomarkers Indicate Potential for Development of Pre-Eclampsia

A pair of novel protein biomarkers has been identified in the blood of asymptomatic pregnant women that can be used to predict the potential onset of pre-eclampsia. Pre-eclampsia (PE) is a disorder... Read more


view channel
Image: The Idylla system is a fully-automated, real-time polymerase chain reaction (PCR) based molecular testing system designed to offer results in a minimal amount of time (Photo courtesy of Biocartis).

Rapid Genomic Profiling of Colon Cancers Improves Therapy Selection

Colorectal cancer is a malignant tumor arising from the inner wall of the large intestine (colon) or rectum. Colorectal cancer is the third leading cause of cancer in both men and women in the USA.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.